Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Acute Leukemia of Ambiguous Lineage

Acute Leukemia of Ambiguous Lineage

24

Pipeline Programs↗

7

Active Trials↗

14

Companies Involved↗

Acute Leukemia of Ambiguous Lineage is an emerging landscape with 24 programs across 14 companies.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

15/100

Mech. Concentration

21/100

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical

No programs

Phase 1

No programs

Phase 224

Idarubicin

Pfizer

Fludarabine

Sanofi

Peripheral Blood Stem Cell

Fred Hutchinson Cancer Center

Recombinant Granulocyte Colony-Stimulating Factor

Fred Hutchinson Cancer Center

Fludarabine Phosphate

Sanofi

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

83%

Small molecule

19 of 23 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.

Analysis

Trial Status

8

clinical trials

Recruiting5 · 63%

Not yet recruiting1 · 13%

Completed1 · 13%

Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia or High-Grade Myeloid Neoplasms: A Randomized Pilot Study

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07094750·50 enrolled

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06317662·153 enrolled

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06013423·54 enrolled

Pilot Study of FLAG-Ida Followed Immediately by Reduced-Intensity Allogeneic HCT for Adults Age 60 and Older With Newly Diagnosed Adverse-Risk AML or Other High-Grade Myeloid Neoplasm

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07046078·20 enrolled

A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

Active, not recruiting·Children's Oncology Group·Phase 2·NCT05761171·78 enrolled

Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06991920·50 enrolled

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT03194932·62 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)